keyword
MENU ▼
Read by QxMD icon Read
search

Paclitaxel

keyword
https://www.readbyqxmd.com/read/28445868/suppressionof-pyruvate-dehydrogenase-kinase-2-re-sensitizes-paclitaxel-resistant-human-lung-cancer-cells-to-paclitaxel
#1
Hong Sun, Anyou Zhu, Xiang Zhou, Fengchao Wang
Despite impressive initial clinical responses, the majority of lung cancer patients treated with paclitaxel eventually develop resistance to the drug. Pyruvate dehydrogenase kinase-2 (PDK2) is a key regulator of glycolysis and oxidative phosphorylation, and its expression is increased in a variety of tumors. In this study, the role of PDK2 in mediating paclitaxel resistance in lung cancer cells was investigated using biochemical and isotopic tracing methods. Increased expression of PDK2 was observed in paclitaxel-resistant cells ascompared totheir parental cells...
April 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/28445625/the-use-of-an-occlusion-perfusion-catheter-to-deliver-paclitaxel-to-the-arterial-wall
#2
Marzieh K Atigh, Emily Turner, Uwe Christians, Saami K Yazdani
AIM: Non-stent drug delivery platforms have recently emerged as an alternative treatment of peripheral arterial disease. Perfusion catheters have the potential to directly deliver anti-proliferative agents to the medial arterial layer to prevent restenosis. The purpose of this study was to therefore determine the effectiveness of a perfusion catheter to deliver paclitaxel, a proven anti-proliferative agent, to combat restenosis. METHODS: A bench-top model was utilized to determine the varying parameters of a novel occlusion perfusion catheter to maximize paclitaxel delivery using pharmacokinetic evaluation and fluorescent microscopy...
April 26, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28443516/synergistic-effect-of-graphene-oxide-coated-nanotised-apigenin-with-paclitaxel-go-na-ptx-a-ros-dependent-mitochondrial-mediated-apoptosis-in-ovarian-cancer
#3
Manish Kumar Pal, Shyam Pyari Jaiswar, Ashish Dwivedi, Shruti Goyal, Vinay Nand Dwivedi, Anumesh Kumar Pathak, Vinod Kumar, Pushp Lata Sankhwar, Ratan Singh Ray
Ovarian cancer is most lethal among all gynecologic malignancies. Paclitaxel (PTX) is well used chemotherapeutic regimen for cancer control; however its undesired toxicity has been always a matter of concern for clinicians. Here we used the graphene oxide coated nanotised apigenin (GO-NA) as chemo sensitizing agent to enhance the efficacy of paclitaxel to overcome the limitations of chemotherapy. GO and GO-Apigenin was prepared by modified Hummers method and the nanoparticles were characterized by dynamic light scattering and transmission electron microscopy Human ovarian adenocarcinomas (SKOV-3) cells was treated by DMSO, Group I (Control)-McCoy's 5A Medium, Group II-Paclitaxel (5nM) alone, Group III- Nanotised Apigenin (GO-NA-10μM) Group IV- Paclitaxel (5nM) + GO-NA (10μM)...
April 24, 2017: Anti-cancer Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/28443468/curcumin-increases-the-sensitivity-of-paclitaxel-resistant-nsclc-cells-to-paclitaxel-through-microrna-30c-mediated-mta1-reduction
#4
Yimin Lu, Jun Wang, Lei Liu, Lequn Yu, Nian Zhao, Xingju Zhou, Xudong Lu
Non-small-cell lung cancer is one of the most lethal cancers in the worldwide. Although Paclitaxel-based combinational therapies have long been used as a standard treatment in aggressive non-small-cell lung cancers, Paclitaxel resistance emerges as a major clinical problem. It has been demonstrated that Curcumin from Curcuma longa as a traditional Chinese medicine can inhibit cancer cell proliferation. However, the role of Curcumin in Paclitaxel-resistant non-small-cell lung cancer cells is not clear. In this study, we investigated the effect of Curcumin on the Paclitaxel-resistant non-small-cell lung cancer cells and found that Curcumin treatment markedly increased the sensitivity of Paclitaxel-resistant non-small-cell lung cancer cells to Paclitaxel...
April 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28441715/targeting-the-bcl-2-family-and-p-glycoprotein-reverses-paclitaxel-resistance-in-human-esophageal-carcinoma-cell-line
#5
Xiaoli Shi, Yinhui Dou, Kairui Zhou, Jinling Huo, Tengjiao Yang, Tiantian Qin, Weihua Liu, Saiqi Wang, Dongxiao Yang, Liming Chang, Cong Wang
Paclitaxel (PTX) is one of the most effective drugs used in the treatment of esophageal cancer, however, paclitaxel resistance represents a key limitation during the treatment process. In this study, we investigated the changes of Bcl-2 family members in the moderate paclitaxel-resistance of esophageal carcinoma EC109/PTX cells both in vitro and in vivo. Moreover, we evaluated the reversal effect using siRNAs and the recombinant inhibitor TW37 targeting Bcl-2, Bcl-XL and Mcl-1. Our findings show that downregulation of Bcl-2, Bcl-XL and Mcl-1 can significantly promote EC109/PTX cell apoptosis and reduce the EC109/PTX cell resistance index (RI)...
April 21, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28441645/saphenous-vein-graft-aneurysm-10-years-after-paclitaxel-eluting-stent-implantation
#6
Akihito Tanaka, Richard J Jabbour, Francesco Giannini, Azeem Latib, Antonio Colombo
A patient underwent paclitaxel-eluting implantation for a saphenous vein graft stenosis. A follow-up angiogram at 8 months demonstrated no restenosis, with multifocal peristent contrast staining. After 10 years, a saphenous vein graft aneurysm was revealed within the stented segment. This late complication should be kept in mind when evaluating patients who have received prior drug-eluting stents.
May 2017: Journal of Invasive Cardiology
https://www.readbyqxmd.com/read/28441502/differential-coupling-of-binding-atp-hydrolysis-and-transport-of-fluorescent-probes-with-p-glycoprotein-in-lipid-nanodiscs
#7
Mavis Jiarong Li, Abhinav Nath, William M Atkins
The ATP-binding cassette transporter P-glycoprotein (ABCB1) plays a major role in cellular resistance to drugs, and drug interactions. Experimental studies support a mechanism with nucleotide-dependent fluctuation between inward-facing and outward-facing conformations, which are coupled to nucleotide hydrolysis. However, detailed insight into drug-dependent modulation of these conformational ensembles is lacking. Different drugs likely occupy partially overlapping but distinct sites, and are therefore variably coupled to nucleotide binding and hydrolysis...
April 25, 2017: Biochemistry
https://www.readbyqxmd.com/read/28441382/hedgehog-signalling-pathway-orchestrates-angiogenesis-in-triple-negative-breast-cancers
#8
Concetta Di Mauro, Roberta Rosa, Valentina D'Amato, Paola Ciciola, Alberto Servetto, Roberta Marciano, Roberta Clara Orsini, Luigi Formisano, Sandro De Falco, Valeria Cicatiello, Maurizio Di Bonito, Monica Cantile, Francesca Collina, Angela Chambery, Bianca Maria Veneziani, Sabino De Placido, Roberto Bianco
BACKGROUND: Several evidences suggest a marked angiogenic dependency in triple-negative breast cancer (TNBC) tumorigenesis and a potential sensitivity to anti-angiogenic agents. Herein, the putative role of Hedgehog (Hh) pathway in regulating TNBC-dependent angiogenesis was investigated. METHODS: Expression and regulation of the Hh pathway transcription factor glioma-associated oncogene homolog1 protein (GLI1) were studied on the endothelial compartment and on TNBC-initiated angiogenesis...
April 25, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28440691/n-butyl-2-cyanoacrylate-based-injectable-and-in-situ-forming-implants-for-efficient-intratumoral-chemotherapy
#9
Yanpu Wu, Luming Wang, Kaili Zhang, Lixiao Zhou, Xiaobing Zhang, Xuecheng Jiang, Chenggang Zhu
The local delivery of chemotherapeutic drugs to tumor sites is an effective approach for achieving therapeutic drug concentrations in solid tumors. Injectable implants with the ability to form in situ represent one of the most promising technologies for intratumoral chemotherapy. However, many issues must be resolved before these implants can be applied in clinical practice. Herein, we report a novel injectable in situ-forming implant system composed of n-butyl-2-cyanoacrylate (NBCA) and ethyl oleate, and the sol-gel phase transition is activated by anions in body fluids or blood...
November 2017: Drug Delivery
https://www.readbyqxmd.com/read/28440494/low-dose-paclitaxel-suppresses-the-induction-of-m2%C3%A2-macrophages-in-gastric-cancer
#10
Takahisa Yamaguchi, Sachio Fushida, Yasuhiko Yamamoto, Tomoya Tsukada, Jun Kinoshita, Katsunobu Oyama, Tomoharu Miyashita, Hidehiro Tajima, Itasu Ninomiya, Seiichi Munesue, Ai Harashima, Shinichi Harada, Hiroshi Yamamoto, Tetsuo Ohta
Tumor-associated macrophages of the M2 phenotype promote tumor proliferation and are associated with a poor prognosis in patients with various malignancies, including gastric cancer with peritoneal dissemination. The present study assessed whether paclitaxel (PTX) suppresses M2 macrophages, by acting as a Toll-like receptor 4 (TLR4) agonist. Macrophages derived from the THP-1 monocytic cell line and peripheral blood mononuclear cell (PBMC)-derived macrophages were cultured with gastric cancer cells in medium containing PTX, at a concentration that did not affect cell proliferation...
April 19, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28440434/preclinical-studies-for-the-combination-of-paclitaxel-and-curcumin-in-cancer-therapy-review
#11
Yumeng Wei, Xinlin Pu, Ling Zhao
Cancer is one of the most common causes of death and remains the first in China and the second in the US. The common treatments for cancer include surgery, radiation, chemotherapy, targeted therapy and immunotherapy, while chemotherapy remains one of the most important treatments. However, the efficacy of chemotherapy is limited due to drug induced-toxicities and resistance, particularly multiple drug resistance (MDR). Therefore, discovery and development of novel therapeutic drugs and/or combination therapy are urgently needed to reduce toxicity and improve efficacy...
April 20, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28440201/investigation-of-the-ph-dependent-cytotoxicity-of-paclitaxel-conjugated-gold-nanoparticles
#12
Zahrah Alhalili, Nur Hikmatul Auliya, Barbara Sandersonb, J G Shapter
Breast cancer, apart from skin cancer, is the most common cancer among women accounting for nearly 1 in 3 cancers and the second leading cause of cancer-related death among women after lung cancer. Finding new approaches to treat such cancers is critically important. OBJECTIVE: This work investigated the ability of a simple system based on paclitaxel conjugated gold nanoparticles (AuNP) to induce efficient cytotoxicity against T47D breast cancerous cells at different pH values. METHOD: The synthesis and characterization of nanoparticles using two approaches is presented...
April 24, 2017: Pharmaceutical Nanotechnology
https://www.readbyqxmd.com/read/28439763/a-phase-ii-multicenter-single-arm-study-of-tri-weekly-low-dose-nanoparticle-albumin-bound-paclitaxel-chemotherapy-for-patients-with-metastatic-or-recurrent-breast-cancer
#13
Shigeru Yamamoto, Noriko Maeda, Yukiko Nagashima, Hidefumi Kubo, Yoko Sato, Hiroto Matsui, Yuka Inoue, Yoshitaro Shindo, Shinsuke Kanekiyo, Kazuhiko Sakamoto, Nobuaki Suzuki, Shigeru Takeda, Tomio Ueno, Shigefumi Yoshino, Shoichi Hazama, Masaaki Oka, Hiroaki Nagano
BACKGROUND: Nanoparticle albumin-bound (nab)-paclitaxel is a solvent-free formulation of paclitaxel that is bound to albumin and has demonstrated improved progression free survival in previous studies of breast cancer. However, it is difficult to treat Japanese patients with metastatic or recurrent breast cancer with the recommended dose of 260 mg/m(2) of (nab)-paclitaxel for more than six cycles due to the occurrence of adverse events. To evaluate the treatment continuity and safety of low-dose nab-paclitaxel, we conducted a phase II study of nab-paclitaxel in patients with metastatic or recurrent breast cancer who had received up to one prior chemotherapy...
April 24, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28438473/bevacizumab-and-paclitaxel-carboplatin-chemotherapy-and-secondary-cytoreduction-in-recurrent-platinum-sensitive-ovarian-cancer-nrg-oncology-gynecologic-oncology-group-study-gog-0213-a-multicentre-open-label-randomised-phase-3-trial
#14
Robert L Coleman, Mark F Brady, Thomas J Herzog, Paul Sabbatini, Deborah K Armstrong, Joan L Walker, Byoung-Gie Kim, Keiichi Fujiwara, Krishnansu S Tewari, David M O'Malley, Susan A Davidson, Stephen C Rubin, Paul DiSilvestro, Karen Basen-Engquist, Helen Huang, John K Chan, Nick M Spirtos, Raheela Ashfaq, Robert S Mannel
BACKGROUND: Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed to explore the roles of secondary surgical cytoreduction and bevacizumab in this population, and report the results of the bevacizumab component here. METHODS: The multicentre, open-label, randomised phase 3 GOG-0213 trial was done in 67 predominantly academic centres in the USA (65 centres), Japan (one centre), and South Korea (one centre)...
April 21, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28437290/remission-following-paclitaxel-and-cisplatin-treatment-in-a-15-year-old-patient-with-unresectable-esophageal-squamous-cell-cancer
#15
Aysenur Bahadir, Erol Erduran, Haluk Sarihan, Gokce P Reis, Adnan Yöney
No abstract text is available yet for this article.
May 2017: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/28436947/dedifferentiation-into-blastomere-like-cancer-stem-cells-via-formation-of-polyploid-giant-cancer-cells
#16
N Niu, I Mercado-Uribe, J Liu
Our recent perplexing findings that polyploid giant cancer cells (PGCCs) acquired embryonic-like stemness and were capable of tumor initiation raised two important unanswered questions: how do PGCCs acquire such stemness, and to which stage of normal development do PGCCs correspond. Intriguingly, formation of giant cells due to failed mitosis/cytokinesis is common in the blastomere stage of the preimplantation embryo. However, the relationship between PGCCs and giant blastomeres has never been studied. Here, we tracked the fate of single PGCCs following paclitaxel-induced mitotic failure...
April 24, 2017: Oncogene
https://www.readbyqxmd.com/read/28436480/dihydromyricetin-induces-apoptosis-and-reverses-drug-resistance-in-ovarian-cancer-cells-by-p53-mediated-downregulation-of-survivin
#17
Yingqi Xu, Shengpeng Wang, Hon Fai Chan, Huaiwu Lu, Zhongqiu Lin, Chengwei He, Meiwan Chen
Ovarian cancer is one of the leading causes of death in gynecological malignancies, and the resistance to chemotherapeutic agents remains a major challenge to successful ovarian cancer chemotherapy. Dihydromyricetin (DHM), a natural flavonoid derived from Ampeopsis Grossdentata, has been widely applied in food industry and medicine for a long time. However, little is known about the effects of DHM on ovarian cancer and the underlying mechanisms. In this study, we demonstrated that DHM could effectively inhibit the proliferation of ovarian cancer cells and induce cell apoptosis...
April 24, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28436298/adenocarcinoma-of-the-appendix-occurring-in-a-patient-treated-with-paclitaxel-for-locally-advanced-esophageal-cancer
#18
Constantin A Dasanu, David M Hyams, Frank J Senatore
Paclitaxel has been linked with a number of immunosuppressive effects such as decreased numbers and activity of dendritic cells, NK-cells and monocytes, which may in turn lead to defective T-cell activation. In addition, this agent was shown to cause mitotic arrest resembling high-grade dysplasia throughout the gastrointestinal tract, including the appendix. We have previously documented a series of lung cancer patients who developed pre-malignant colonic polyps and/or colon cancer either during or weeks following chemotherapy with paclitaxel, suggesting a potential role of this agent in their pathogenesis...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28436252/cost-effectiveness-and-safety-of-ramucirumab-plus-paclitaxel-chemotherapy-in-the-treatment-of-advanced-and-recurrent-gastric-cancer
#19
Michio Kimura, Eiseki Usami, Hitomi Teramachi, Tomoaki Yoshimura
Introduction Weekly paclitaxel (PTX), irinotecan (CPT-11) and ramucirumab plus paclitaxel (Ram + PTX) are currently recommended as the standard second-line or later chemotherapies for advanced and recurrent gastric cancer. This study aims to compare the cost-effectiveness of using Ram + PTX vs. PTX or CPT-11. Furthermore, we investigated the safety and treatment continuity of Ram + PTX in Japan. Methods Expected costs were calculated based on data from patients with advanced and recurrent gastric cancer who were treated with PTX, CPT-11 and Ram + PTX...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28436242/current-status-of-ramucirumab-in-gastroesophageal-adenocarcinoma
#20
Elena Elimova, Quan Lin, Shumei Song, Jaffer A Ajani
Outcomes of patients with advanced gastric or gastroesophageal junction adenocarcinoma (GEAC) remain poor despite recent advances. The standard of care in the management of this disease had not changed much over the past decade. In the first line, a platinum containing doublet/triplet is used, while in <20% of patients with human epithelial growth factor receptor type 2 overexpressing GEACs, trasuzumab can provide a modest advantage. Until recently, no standard second-line regimens existed; however, the results of the REGARD and RAINBOW trials led to the approval of ramucirumab in the second-line setting...
April 24, 2017: Future Oncology
keyword
keyword
35091
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"